RNP Inc.

RNP Inc

Overview

RNP Inc. (アールエヌピー株式会社, Āru Enu Pī Kabushiki-gaisha) is a Japanese biotechnology company headquartered in Tokyo, Japan, specializing in RNA-based therapeutics and diagnostics for neurodegenerative diseases. Founded in 2016, RNP focuses on developing RNA-based drugs that target the underlying genetic causes of Alzheimer's disease, Parkinson's disease, and other neurological disorders.

Company Information

| Attribute | Details |
|-----------|---------|
| Stock Ticker | TSE 4976 |
| Headquarters | Tokyo, Japan |
| Founded | 2016 |
| CEO | Dr. Ken Tanaka |
| Website | https://www.rnp.co.jp/ |
| IPO | Tokyo Stock Exchange Growth Market (2020) |

Company Background

RNP Inc. was established in 2016 as a spin-off from the University of Tokyo's Institute of Medical Science, based on research in RNA biology and gene expression regulation. The company's name stands for "RNA and Nucleic acid Pharmaceutical," reflecting its focus on RNA-based therapeutics.

The company went public on the Tokyo Stock Exchange Growth Market in 2020, raising funds to advance its pipeline of RNA therapeutics for neurodegenerative diseases.

Technology Platform

RNP has developed several proprietary technology platforms:

RNP Inc

Overview

RNP Inc. (アールエヌピー株式会社, Āru Enu Pī Kabushiki-gaisha) is a Japanese biotechnology company headquartered in Tokyo, Japan, specializing in RNA-based therapeutics and diagnostics for neurodegenerative diseases. Founded in 2016, RNP focuses on developing RNA-based drugs that target the underlying genetic causes of Alzheimer's disease, Parkinson's disease, and other neurological disorders.

Company Information

| Attribute | Details |
|-----------|---------|
| Stock Ticker | TSE 4976 |
| Headquarters | Tokyo, Japan |
| Founded | 2016 |
| CEO | Dr. Ken Tanaka |
| Website | https://www.rnp.co.jp/ |
| IPO | Tokyo Stock Exchange Growth Market (2020) |

Company Background

RNP Inc. was established in 2016 as a spin-off from the University of Tokyo's Institute of Medical Science, based on research in RNA biology and gene expression regulation. The company's name stands for "RNA and Nucleic acid Pharmaceutical," reflecting its focus on RNA-based therapeutics.

The company went public on the Tokyo Stock Exchange Growth Market in 2020, raising funds to advance its pipeline of RNA therapeutics for neurodegenerative diseases.

Technology Platform

RNP has developed several proprietary technology platforms:

RNA Interference (RNAi) Technology

• SiRNA (small interfering RNA): Sequence-specific gene silencing
• MiRNA mimics and inhibitors: Modulation of microRNA expression
• ShRNA (short hairpin RNA): Long-term gene knockdown

Antisense Oligonucleotide (ASO) Technology

• Splice-modulating ASOs: Correction of abnormal RNA splicing
• Translation-blocking ASOs: Prevention of problematic protein translation
• RNase H-dependent ASOs: Degradation of target mRNA

RNA Delivery Systems

• GalNAc conjugation: Liver-targeted delivery
• Lipid nanoparticles (LNP): Systemic delivery
• Brain-targeted delivery: Crossing the blood-brain barrier

Neurodegeneration Programs

Alzheimer's Disease Pipeline

RNP is developing several programs for Alzheimer's disease:

APOE4 Targeting

• RNP-401: ASO targeting APOE4 expression in the brain
• Mechanism: Reduces production of APOE4 protein, a major genetic risk factor
• Status: Preclinical, IND-enabling studies

Tau Targeting

• RNP-402: RNAi therapeutic targeting MAPT gene (tau)
• Mechanism: Reduces tau protein production in neurons
• Status: Discovery phase

BACE1 Modulation

• RNP-403: ASO modulating BACE1 expression
• Mechanism: Reduces amyloid-beta production by modulating BACE1

Parkinson's Disease Pipeline

Alpha-Synuclein Targeting

• RNP-501: RNAi therapeutic targeting SNCA (alpha-synuclein gene)
• Mechanism: Reduces alpha-synuclein protein production
• Status: Preclinical

LRRK2 Targeting

• RNP-502: ASO targeting LRRK2 mutation carriers
• Mechanism: Modulates expression of mutant LRRK2 protein

Other Programs

ALS

• RNP-601: ASO targeting C9orf72 repeat expansions
• RNP-602: SOD1-targeting RNAi therapeutic

Huntington's Disease

• RNP-701: ASO targeting mutant huntingtin (HTT) gene

Strategic Partnerships

RNP has established collaborations with:

• Takeda Pharmaceutical: Option agreement for neurological disease programs
• Moderna Therapeutics: Collaboration on mRNA-based therapies
• University of Tokyo: Academic research partnership
• Kyoto University: CiRA collaboration on iPSC-based validation

Diagnostics Division

RNP also has a diagnostics division focused on:

• Biomarker discovery: RNA-based biomarkers for neurodegenerative diseases
• Diagnostic tests: Development of RNA-based diagnostic assays
• Companion diagnostics: Tests to identify patients who may benefit from specific therapies

Pipeline Summary

| Product | Indication | Modality | Development Stage |
|---------|------------|----------|-------------------|
| RNP-401 | Alzheimer's (APOE4) | ASO | Preclinical |
| RNP-402 | Alzheimer's (Tau) | RNAi | Discovery |
| RNP-501 | Parkinson's (α-syn) | RNAi | Preclinical |
| RNP-601 | ALS (C9orf72) | ASO | Discovery |
| RNP-701 | Huntington's | ASO | Discovery |

Financial Overview

• Market capitalization: Approximately ¥8-12 billion
• Cash reserves: Strong following 2023 financing
• R&D budget: Approximately ¥1 billion annually

Cross-Links to NeuroWiki

• [Alzheimer's Disease](/diseases/alzheimers-disease) - Primary indication
• [Parkinson's Disease](/diseases/parkinsons-disease) - Primary indication
• [APOE Gene - Genetic target](/genes/apoe)
• [MAPT Gene - Tau gene target](/proteins/tau)
• [SNCA Gene - Alpha-synuclein gene](/proteins/alpha-synuclein)
• [LRRK2 Gene - Parkinson's target](/proteins/parkin)
• [RNA Interference](/technologies/rna-interference)
• [Antisense Oligonucleotides](/technologies/antisense-oligonucleotides)

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References